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Abstract

Herpes simplex virus type 1 (HSV-1) is the causative agent of oral herpes, and is able to
establish lifelong latent infection along with painful, recurring symptoms. Epigallocatechin-3gallate (EGCG) is the most abundant polyphenol derived from green tea (Camellia sinensis),
whose anti-inflammatory, antioxidant, anti-cancer, and antiviral properties have been widely
studied. Although EGCG is not chemically stable and has poor hydrophobicity, lipophilic
derivatives of EGCG have shown increased stability as well as increased antiviral efficacy
against HSV. Previous studies have demonstrated that EGCG stearate (EGCG-S), a derivative of
EGCG esterified at the 4’ position with stearic acid, is able to inhibit HSV-1 infection in cell
culture. However, the mechanism of action of EGCG-S has not been fully determined. Since
EGCG has been shown to inhibit HSV infection by interrupting viral attachment to cell
membrane receptors, it is hypothesized that EGCG-S inhibits HSV-1 infection by blocking
virion binding in a similar fashion. Through luminescence-based assays, this project investigates
the anti-HSV-1 mechanism of EGCG-S in human epithelial cells, with specific focus on
inhibition of HSV-1 binding. Antiviral effect was found to occur in a dose-dependent manner,
with 85.87 ± 0.07% inhibition exerted by 100 μM EGCG-S and 29.51 ± 0.13% inhibition by 75
μM. Upon assessment of inhibition of HSV-1 penetration, 75 and 50 μM EGCG-S caused 44.9 ±
0.2% and 40.5 ± 0.2% inhibition respectively, whereas 100 μM EGCG-S showed 63.23 ± 0.13%
inhibition. Lastly, investigation of inhibition of HSV-1 at the initial binding step revealed that
treatment with 75 μM EGCG-S resulted in 43.4 ± 0.2% inhibition, while 100 μM resulted in
97.89 ± 0.11% inhibition, virtually complete inhibition of HSV-1 binding.
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Background: Literature Review

Herpes simplex virus type 1 Infection: Epidemiology and Prevalence
Herpes simplex virus type 1 (HSV-1) causes oral and genital herpes, lifelong, contagious
infections that represent a significant global health burden. The World Health Organization
estimates that 67% of the world’s population ages 0-49 is infected with HSV-1, and more than
50% of adults in the United States are seropositive (Looker et al., 2015). Although HSV-1 has
been classically associated with oral herpes, which causes exhibition of cold sores in and around
the mouth area, HSV-1 causes lesions in the genital mucosa as well. Over the past few decades,
the causative agent of genital herpes in developed countries has increasingly been HSV-1,
principally in individuals under the age of 25 (Ryder et al., 2009). In young women, HSV-1 has
recently become more common as the cause of both oral and genital herpes infections, with the
rate of HSV-1 infection being twice as likely as HSV-2 infection (Bernstein et al., 2012).
There are other more severe forms of HSV-1 infection, some potentially fatal, such as
encephalitis, necrotizing stromal keratitis, and neonatal herpes. Herpes Simplex Encephalitis
(HSE) is the most deadly viral encephalitis; it has been associated with 30% mortality and severe
neurological defects in treated patients, and 70% mortality in untreated patients (Steiner, 2011).
Ocular HSV-1 infection is a leading cause of infectious blindness in developed countries, and
leads to 40,000 new cases of severe visual impairment arising on a yearly basis (Farooq and
Shukla, 2012). Necrotizing stromal keratitis, an HSV-1 infection of the cornea, leads to
decreased corneal sensation, scarring, and blindness occurring as a result of immune response to
HSV-1 (Azher et al., 2017). Neonatal herpes is caused by transmission of HSV-1 from mother
exhibiting genital infection to child during birth, and can cause severe neurological disease or
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death to the newborn (Belshe et al., 2012). In the United States, there are 1,500 cases of neonatal
herpes yearly (George et al., 2014).
Transmission occurs by direct contact with lesions, through oral-to-oral contact or oralgenital contact, or through contact with infected oral or genital secretions during asymptomatic
viral shedding (Ramchandani et al., 2016). The site of primary infection is at the epithelia of the
oral or genital mucosa, followed by establishment of latent infection of the peripheral sensory
nervous system (Khoury-Hanold et al., 2016), namely, the sensory neurons in the trigeminal
ganglion (Maroui et al., 2016). Infection can be lytic or latent; latent HSV-1 can be reactivated
by stress, such as heat or sickness. Upon reactivation, virions travel down the neuronal axon to
re-infect the epithelial cells, a process termed secondary infection. This accounts for the
recurring nature of herpes symptoms over the duration of an infected individual’s lifetime.
Classification and Lifecycle
HSV-1 is an alphaherpesvirus, subfamily Alphaherpesvirinae, and is one of eight
herpesviruses. It is a spherical, enveloped, double-stranded DNA virus with a diameter ranging
from 155 to 200 nm (Brown and Newcomb, 2011). The viral DNA contains unique long (UL)
and unique short (US) regions flanked by repeat regions (RL and RS) (Kennedy et al., 2015). The
icosahedral nucleocapsid at the virion core has a diameter of 125 nm, and encases the genetic
material (Brown and Newcomb, 2011). The nucleocapsid is surrounded by partially ordered
protein tegument (Laine et al., 2015), which, in turn, is enclosed in a lipid envelope. Embedded
in the lipid envelope are 12 expected glycoproteins involved in attachment, entry, and egress
(Lamers et al., 2015).
The lifecycle of HSV-1 begins with primary infection of epithelial cells of the oral or
genital mucosa. Generally speaking, attachment of enveloped viruses to host cells occurs upon
2

proper interaction between glycoproteins present on the viral envelope surface and cellular
receptors; hence, these glycoproteins are critical for viral pathogenesis, as well as providing
tissue tropism to the virus (Banerjee and Mukhopadhyay, 2016). While the herpesvirus entry
pathway into host cells differs by cell type (Sayers and Elliott, 2016), required entry machinery
includes viral glycoproteins glycoprotein D (gD), gC, and the gH/L heterodimer. gB is a class III
fusogenic protein essential for HSV-1 infectivity, thought to undergo a conformational change
that provides energy for membrane fusion (Fan et al., 2017). Glycoprotein K is conserved among
alphaherpesviruses, and the extracellular amino terminus of gK is non-essential, but important in
the entry of HSV-1 into neurons through axonal termini, as well as playing an important role in
membrane fusion (Rider, 2017).
The steps of HSV-1 entry are reviewed by Agelidis and Shukla (2015), and are as
follows. Initiation of viral infection begins with low-affinity interaction between gB and/or gC
with heparan sulfate proteoglycans (HSPGs), often on the filopodia of the host cell. Viral
surfing, which is the movement of the virus down the filopodia and towards the cell body, will
subsequently occur. This is followed by a high affinity interaction between gD and one of its
receptors, herpesvirus entry mediator (HVEM), nectin-1, nectin-2, or 3-O-sulfated heparan
sulfate (3-O-HS). This binding activates the fusogenic complex, a concerted interaction between
gD, gB, and the gH/gL heterodimer. Lastly, fusion of the viral envelope membrane with the cell
membrane is initiated when gB binds to one of its receptors, paired immunoglobulin-like type 2
receptor α (PILRA), non-muscle myosin IIA (NMMHC-IIA), or myelin-associated glycoprotein
(MAG). Entry of the virion into the host cell can occur either through pH-independent fusion of
the membranes, or through pH-dependent or pH-independent endocytosis (Sayers and Elliott,
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2016). Following viral entry, the capsid is released into the cytoplasm and docks at a nuclear
pore, and the genome is inserted into the nucleus (Huffman et al., 2017).
Transcription of viral genes takes place as

in a temporal fashion, beginning with

transcription of immediate early (IE) genes, followed by early (E) genes, and ending with late
(L) genes, followed by protein expression. IE genes are involved in the activation of transcription
of E genes, as well as in the evasion of immune response. For example, immediate-early HSV-1
proteins ICP47 and Us3 inhibit MHC-I antigen presentation in cells infected with HSV-1,
allowing these cells to prevent elimination by cytotoxic CD8+ T-lymphocytes (Oldham et al.,
2016; Imai et al., 2013). Early genes code for enzymatic/non-structural viral proteins, while late
genes mainly code for structural proteins. Early-late proteins are first expressed at a low level
then upregulated during DNA synthesis, while true-late proteins are involved in assembly of
progeny virions, and expressed only after DNA replication (Kulej et al., 2017). Activation of
transcription is accomplished in part upon release of VP16 from the viral tegument, interaction
with the cellular POU domain protein Oct-1, and recruitment to the viral immediate-early
enhancer elements (Kristie, 2015).
Synthesis of viral DNA as well as assembly and packaging of the viral nucleocapsid
occur in discrete replication compartments in the nucleus (Weller and Coen, 2012; Kulej et al.,
2017). As reviewed by Dembowski et al., viral DNA replication requires a minimum of seven
viral replication proteins; the helicase/primase complex (UL5/UL8/UL52) serves to unwind and
prime the DNA, which subsequently activates DNA synthesis by the two subunit viral DNA
polymerase (UL30/UL42) (2017). DNA synthesis is followed by the assembly and release of
progeny virions from host cells, processes which are made possible through the coordinated
activities of the viral protein kinases US3 and UL13 (Gershburg et al., 2015). Under lytic
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conditions, progeny virions are produced within 4-6 hours post infection (Dembowski et al.,
2017), followed by cell lysis and spread of infection to neighboring cells, resulting in the
formation of fever blisters in the epithelia.
HSV-1 is neurotropic (Rider, 2017) and can establish latency; nerve endings innervating
the orofacial mucosa provide a route for virions to travel up the axon and latently infect the cell
body of the neuron, located in the trigeminal ganglion. Latency associated transcript (LAT), a
viral non-protein coding RNA, is expressed and serves to suppress the transcription of lytic
phase genes (Nicoll et al., 2016). Initiation of latency is influenced by interaction of the viral
genome with the nuclear environment, namely the association of viral DNA with promyelocytic
protein (PML) to form PML-nuclear bodies (Maroui et al., 2016). Maroui et al. found that single
replication in the neuron nucleus was associated with no expression of LATs, while multiple
sites of replication was associated with expression of LATs (2016).
Upon physiological stressors in the host, the latent HSV-1 genome in the neuronal cell
body is reactivated. Transition to the lytic life cycle requires transactivation of VP16, an essential
viral tegument protein; infected cell protein 0 (ICP0) has also been implicated in initiation of
reactivation (Sawtell and Thompson, 2016). Upon reactivation, previously latent HSV-1
genomes are transcribed and replicated, and newly-assembled progeny virions travel down the
axon to infect the epithelial cells at the mucosal surface, resulting in the formation of ulcers
(Thellman and Triezenberg, 2017).
Current Treatments and Prevention Strategies
There is no cure for herpes. Current treatments include nucleoside analogs, acyclovir
(ACV) and penciclovir (PCV), and their respective prodrugs, valacyclovir and famciclovir.
These drugs target DNA polymerase and function as DNA chain terminators; they reduce viral
5

propagation by the suppression of viral replication. Acyclovir has a virustatic mode of action and
has been shown to be more effective on early-stage cold sores (Houston et al., 2017). Although
drugs like acyclovir are effective antivirals, the global burden of HSV-1 infection is increasing
rather than decreasing, highlighting the need for additional treatment strategies. Moreover,
multi-drug resistant strains of HSV-1 have emerged and are frequently found in
immunocompromised patients, emphasizing the urgency of developing novel modes of
prevention and treatment (Piret and Boivin, 2011).
Efforts in development of a vaccine have focused on specifically mutated attenuated viral
candidates, DNA vaccines, hybrid recombinant viruses, or recombinant viral proteins (Sandgren
et al, 2016). Sandgren et al. asserts that although adaptive immune response against HSV-1 can
be induced through the combination of an adjuvant with recombinant viral proteins, success has
only been partial. An HSV-2 glycoprotein D-based vaccine was found to be 58% effective (95%
confidence interval, 12 to 80%) in preventing HSV-1 genital disease and infection in
seronegative women, but not in men or seropositive individuals (Belshe et al., 2012). Antiviral
efficacy of the vaccine Simplirix (gD/AS04) against genital HSV-1 infection in the cotton rat
Sigmodon hispidus model was shown to be 50-60% effective at a 2 μg dose (Boukhvalova et al.,
2015).
A contributing factor in the partial failure of recent vaccine trials could be genetic
variation in strains of HSV-1 (Szpara et al., 2014). For example, viral glycoprotein B has been
the basis of many vaccine strategies, and the first 80 amino acid residues of gB include a binding
site for MHC II proteins on antigen-presenting cells, which play a key role in development of
immunity. However, Szpara et al. (2014) revealed that these 80 residues are highly variable
among viral strains, which poses a distinct challenge in the production of a broadly effective
6

immune response. Although these challenges exist, efforts are ongoing; in a study of the
comparison of two potential prophylactic vaccines, a live attenuated HSV-1 vaccine (0ΔNLS)
and a glycoprotein D subunit (gD-2), 0ΔNLS more effectively protected against replication,
dissemination, and latency establishment of HSV-1 in mice (Royer et al., 2016). Additionally, it
is important to emphasize that as part of efforts to reduce the spread of HSV-1 infection, topical
microbicides are a possible alternative to vaccination (Isaacs et al., 2011), as are topical
ointments containing natural products (Hsu, 2015).
Natural Products as Antivirals
Natural products have been an excellent source of biologically active molecules;
approximately 25% of active compounds discovered from 1981 to 2014 were natural products or
were derived from natural products (Newman et al., 2016) Importantly, many plant-based
compounds have been shown to specifically possess activity against HSV-1 (Hassan and
Berchová, 2015). Recent studies have highlighted the antiviral activity of phytochemicals such as
curcumin, pomegranate rind extract, and Cornus canadensis extract against HSV-1.
Curcumin, the primary component of turmeric, and two modified curcumin compounds
inhibited HSV-1 infection in cell culture with IC50 values of 33.0 μg/mL, 13.9 μg/mL and 23.1
μg/mL, respectively (Zandi et al., 2010). Pomegranate rind extract (PRE), which contains major
bioactive compounds punicalagin and ellagic acid, was shown to have antiviral activity against
HSV-1 in cell culture with an IC50 of 0.560 ± 0.039 μg/mL (Houston et al., 2017). Extract of C.
canadensis, a plant used in traditional Native American medicine, was found to contain bioactive
hydrolysable tannins, and was tested as an antiviral during different stages of HSV-1 infection in
Vero cells. At a concentration of 100 μg/mL, the leaf extracts inhibited HSV-1 at the absorption
and replication steps, as demonstrated by inhibition of 69 to 94% plaque formation at both steps,
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and an absorption EC50 of 9 μg/mL. The leaf extract also directly inhibited HSV-1 virions, as
shown by 90 to 100% plaque reduction and an EC50 of 17 μg/mL (Lavoie et al., 2017).
Tea Polyphenols
A rich source of natural products that have been investigated for antiviral properties are
tea polyphenols. Tea is the second most consumed beverage worldwide, and is derived from
leaves of the plant Camellia sinensis. Depending on the method of processing the tea leaves,
black tea, oolong tea, or green tea can be produced. Black tea is made through a process of
crushing the tea leaves to promote oxidation, followed by fermentation, which consists of
enzymatic oxidation and results in the production of theaflavins and thearubigins (Kanwar et al.,
2012; Tenore, 2015). Green tea, in contrast, is produced by steaming and drying of the tea
leaves, a process that does not include oxidation or fermentation (Oz, 2017). Catechins, a group
of polyphenolic flavanoids present in tea, are distinguishable by a benzopyran group including at
least one aromatic ring (Botten et al., 2015). Structurally, the characteristics that contribute to the
biological activity of these tea polyphenols are the presence of the galloyl moiety, as well as the
number and position of the hydroxyl groups, which allow for hydrogen bonding with biological
molecules (Botten et al., 2015).
Black tea theaflavins have been shown to possess antiviral activity against HSV-1. Isaacs
and Wu demonstrated that a combination of 100 μM theaflavin-3,3’-digallate (TF-3) and 1%
lactic acid almost completely deactivated clinical isolates of HSV-1, as evidenced by a three-fold
to five-fold reduction in viral titer (2013). de Oliveira showed that at a concentration of 50 μM,
TF-3 decreased the production of HSV-1 particles by >99% in Vero and A549 cells, by direct
action on virions rather than on host cells (2015). In addition to the encouraging studies
highlighting the antiviral properties of theaflavins derived from black tea, a plethora of studies
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have investigated the bioactivity of polyphenols derived from green tea, as discussed in the
following section.
EGCG
͑
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ΖΡΚΘΒΝΝΠΔΒΥΖΔΙΚΟ͙͑Ͷʹ͚͙͚͑͜͝͞ΖΡΚΔΒΥΖΔΙΚΟ͙͑Ͷʹ͚͙͚͑͝͞ΖΡΚΔΒΥΖΔΙΚΟ͑ΘΒΝΝΒΥΖ͑
͙Ͷʹ͚͑͝ΒΟΕ͙͚͑͞ΖΡΚΘΒΝΝΠΔΒΥΖΔΙΚΟͤ͞͞ΘΒΝΝΒΥΖ͙͑Ͷʹ͚͑͝Ͷʹ͑ΚΤ͑ΡΣΖΤΖΟΥ͑ΚΟ͑
ΥΙΖ͑ ΘΣΖΒΥΖΤΥ͑ ΒΓΦΟΕΒΟΔΖ͑͟ Ͷʹ͑ ΒΝΤΠ͑ ΡΠΤΤΖΤΤΖΤ͑ ΥΙΖ͑ ΘΣΖΒΥΖΤΥ͑
ΓΚΠΒΔΥΚΧΚΥΪ͑͝ ΠΗΥΖΟ͑ ΒΥΥΣΚΓΦΥΖΕ͑ ΥΠ͑ ΥΙΖ͑ ΡΣΖΤΖΟΔΖ͑ ΠΗ͑ ΥΙΖ͑ ΘΒΝΝΠΪΝ͑ ΞΠΚΖΥΪ͑
ΒΟΕ͑ ΙΪΕΣΠΩΪΝ͑ ΘΣΠΦΡΤ͑ ΥΙΒΥ͑ ΚΟΔΣΖΒΤΖ͑ ΥΙΖ͑ ΒΓΚΝΚΥΪ͑ ΠΗ͑ ΥΙΚΤ͑ ΔΠΞΡΠΦΟΕ͑ ΥΠ͑
ΚΟΥΖΣΒΔΥ͑ ΨΚΥΙ͑ ΓΚΠΝΠΘΚΔΒΝ͑ ΞΠΝΖΔΦΝΖΤ͑ ΥΙΣΠΦΘΙ͑ ΥΙΖ͑ ΗΠΣΞΒΥΚΠΟ͑ ΠΗ͑
ΙΪΕΣΠΘΖΟ͑ΓΠΟΕΤ͙͑͑ͳΠΥΥΖΟ͑ΖΥ͑ΒΝ͚͑ͣͦ͑͟͢͟͝͡Ͷʹ͑ΚΤ͑Β͑ΤΞΒΝΝ͑ΞΠΝΖΔΦΝΖ͑͝ΨΚΥΙ͑Β͑
ΞΠΝΖΔΦΝΒΣ͑ ΨΖΚΘΙΥ͑ ΠΗ͑ ͥͦͩͤͨͣ͑͟ Θ͠ΞΠΝ͑͝ ΒΟΕ͑ ΚΤ͑ ΤΥΣΦΔΥΦΣΒΝΝΪ͑ ΔΠΞΡΠΤΖΕ͑ ΠΗ͑
ΗΠΦΣ͑ ΣΚΟΘΤͬ͑ Β͑ benzenediol ring (A) connected to a pyrogallol ring (B), a tetrahydropyran
moiety (C), and a galloyl group (D ring) (Botten, 2015).
Properties of EGCG include antioxidant, anti-cancer, and anti-inflammatory (Das et al.,
2014). While EGCG has been primarily recognized as an potent antioxidant (Zhao et al., 2014),
more recent studies have shown that EGCG can behave as a pro-oxidant or antioxidant
depending on the cellular redox environment, including high levels of oxidant scavenging
proteins and oxidized proteins and lipids (Kim et al., 2014). EGCG is able to bind to cells, and
the gallate group (D ring) as well as the tri-hydroxyl structure of the B ring are crucial for this
activity (Yano et al., 2007). Moreover, EGCG has been shown to interact directly with
phospholipids and membrane proteins (Kim et al., 2014).
9

EGCG has protective properties in neurodegenerative diseases, such as Alzheimer’s and
Parkinson’s, as well as chemopreventive activity against a broad range of cancers. In a mouse
model of Alzheimer's disease, EGCG has been shown to decrease beta and gamma secretase
activity, thus reducing the production of beta amyloid while promoting degradation (Lim et al.,
2013). EGCG was also demonstrated to exert neuroprotective effects in a mouse model of
Parkinson’s disease through modulation of peripheral inflammation that plays a role in disease
progression (Zhou et al., 2018). EGCG possesses the ability of moderating the cellular responses
present in cancer, through the binding and modulation of signaling molecules associated with
mitosis (Rahmani et al., 2015). Tsai et al. found that EGCG induced cell death and generated
reactive oxygen species in a primary effusion lymphoma cell line (2018).
EGCG possesses antiviral activity against a wide range of viruses including Zika virus
(ZIKV) (Vázquez-Calvo et al., 2017), hepatitis C virus, and herpesviruses. At 50 μM, EGCG
was shown to act directly on hepatitis C virions to inhibit over 90% of infection in HuhǦ 7 cell
culture (Calland et al., 2012). More recently, EGCG was shown to enhance poly I:C-mediated
hepatitis C virus inhibition in JFH-1-Huh7 cells at both RNA and protein levels (Wang et al.,
2017). EGCG inhibited replication and reactivation of Kaposi’s sarcoma-associated herpesvirus
(KSHV), an oncogenic herpesvirus, in primary effusion lymphoma cells (Tsai et al., 2018).
Digallate dimers of EGCG were shown to inhibit HSV-1 infection at 100 μM concentration
through inactivation of viral particles, possibly through the binding of envelope glycoproteins
(Isaacs et al., 2011). Colpitts and Schang demonstrated that EGCG decreased HSV-1 infectivity
in cell culture with an EC50 0.1 μM, through interaction with viral glycoproteins. Furthermore,
EGCG was shown to compete for heparan sulfate binding, thus inhibiting virion attachment to
heparan sulfate-or sialic acid-containing glycans (2014).
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EGCG-S
Although having been shown to possess antiviral activity, EGCG is prone to rapid
metabolism and possesses poor membrane permeability and low chemical stability (Mereles and
Hunstein, 2011). EGCG is also unstable under cell culture conditions, undergoing auto-oxidation
and the production of H2O2 (Shuang et al., 2014). However, modified derivatives of EGCG have
been found to exhibit increased lipophilicity and stability, while still possessing antiviral activity
(Hsu, 2015). Addition of a fatty acid, such as palmitoyl, to the B or D ring of EGCG prolonged
the half life by seven-fold in cell culture medium (Jung et al., 2015). One such modified
compound, EGCG-Stearate (EGCG-S), contains a stearic acid, which is an 18-C unsaturated
fatty acid, esterified to the 4’ position of the B ring.
EGCG-S has been demonstrated to be useful as an antiviral agent against HSV-1. A case
study demonstrated that topical application of a proprietary formulation containing EGCG-S
prevented progression of lesions and shortened the duration of symptoms (Zhao et al., 2012). A
similar compound, palmitoyl-EGCG, modified by the addition of a 16-C fatty acid, was shown to
be a more potent antiviral against HSV-1 that EGCG, with a concentration of 75 μM yielding
more than 99% inhibition of infection in Vero cells (De Oliveira et al., 2013). A double-blind,
placebo-controlled, randomized phase II clinical trial of AverTeaX, a topical formula containing
lipophilic EGCG, was conducted to determine its effect on herpes labialis. Patients exhibited
shortened duration of symptoms as well as shortened blister and ulceration stages, suggesting
that AverTeaX inhibited HSV-1 infection in a clinically significant manner (Zhao et al., 2015).
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Prevention of Binding?
The mechanism of action of antiviral compounds can differ by targeting different phases
in the viral life cycle, e. g. inhibition at the entry step or inhibition at the replication step. Recent
studies suggest that the antiviral mechanism of action of many polyphenolic natural products
against HSV-1 targets initial binding and entry. C. canadensis extract, which contains
polyphenolic tannins, was shown to inhibit HSV-1 infection at the absorption step with EC50 of
9 μg/mL1 (Lavoie et al., 2017). Theaflavin-3,3’-digallate inhibited entry of HSV-1 into A549
cells through blocking the absorption and penetration steps (de Oliveira et al., 2015). EGCG was
shown to inhibit attachment of HSV-1 to cell surface heparan sulfate-or sialic acid-containing
glycans (Colpitts and Schang, 2014).
This trend in the antiviral mechanism of action of EGCG has been correspondingly
shown against other viruses. EGCG, at a concentration of 50 μM, functions as a direct-acting
antiviral by impairing the ability of the hepatitis C virus to bind to the host cell, thus inhibiting
entry (Calland et al., 2012). In a study assessing the antiviral activity of EGCG against a diverse
group of enveloped and non-enveloped viruses, EGCG was shown to directly but nonspecifically bind to viral proteins, thus inhibiting viral binding to host cells (Colpitts and Schang,
2014).
Since one of the main antiviral modes of action of green tea catechins has been
demonstrated to be inhibition at the entry/absorption step (Xu et al., 2017), it is hypothesized that
the lipophilic derivative of EGCG, EGCG-S, inhibits HSV-1 infection through this mechanism
as well. The current study focuses on the inhibition of lytic infection of HSV-1 in human
epithelial cell culture, through in vitro treatment of HSV-1 virions by EGCG-S. Specifically, this
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study aims to provide insights into the anti-HSV-1 mechanism of action of EGCG-S, for the
ultimate goal of preventing spread of infection and developing effective therapeutic strategies.

MATERIALS AND METHODS
Cell Culture and Virus
A579 cells, adenocarcinomic human alveolar basal epithelial cells (ATCC CCL-185),
were maintained in Ham’s F-12K medium, supplemented with 10% fetal bovine serum (Serum
Source International) and 1% gentamicin sulfate (10 mg/mL, BioWhittaker), and incubated at 37
°C and 5% CO2. For all assays, a 1:5 split of a confluent T25 flask was plated in 96-well plates,
6-well plates, or 24-well plates, and incubated for 24 hours until 80-90% confluence was
achieved. Subsequently, infection and treatment were performed.

GHSV-UL46 (ATCC VR-1544), a recombinant strain of HSV-1, was utilized in all
experiments. GHSV-UL46 is labeled with a green fluorescent protein, accomplished by the
fusion of GFP to the structural tegument protein VP11/12 (Willard, 2002). Preparation of virus
stocks was performed by infection of a T75 flask of A549 cells for 1 hr at 37 °C and 5% CO2,
followed by aspiration unabsorbed virus and addition of media. When full cytopathic effect was
observed, the contents of the flask were harvested and centrifuged at low speed for 5 minutes.
The supernatant containing purified virus was aliquoted into 1.5 mL cryogenic tubes and stored
at -80 °C.
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EGCG-Stearate
EGCG-S (US Patent 20120172423, Camelix) was dissolved in DMSO at a stock
concentration of 50 mM. Further dilutions were made using Ham’s F-12K media supplemented
with 10% FBS, and all solutions were stored at 4 °C.
Viral Titer Determination
Titer of HSV-1 stocks were determined through endpoint dilution assays. A549 cells
were grown for 24 hours in a 24-well plate until 70-80% confluent, and media was aspirated
from each well. A ten-fold serial dilution of HSV-1 was made, and 100 μL of viral dilutions were
placed in each well, four wells per dilution, including media-only controls. Following a 1 hour
incubation at 37 °C and 5% CO2, unabsorbed virus was aspirated, and 0.5 mL fresh media was
placed in each well. The plate was observed for approximately 3 days, and the last dilution of
HSV-1 which yielded full cytopathic effect (CPE) was visually determined through the use of a
Biostar inverted microscope (Reichert).
Cytotoxicity Assays
For a quantitative assessment of cytotoxicity, A549 cells were grown for 24 hours in a
96-well plate until 70-80% confluent. Solutions of 100, 75, 50 μM EGCG-S were made, and
DMSO controls of equal volume were made, yielding 2, 1.5., 1% DMSO. Of each solution, 100
μL were placed in each well (5 wells per treatment). The plate was incubated for 1 hour at 37 °C
and 5% CO2, 100 μL PBS were added to each well, and PBS as well as EGCG-S solution were
shaken out of the plate. Fresh media was placed in each well including blank wells containing no
cells, and the plate was incubated for 48 hours at 37 °C and 5% CO2. To determine cell viability,
the CellTiter 96 AQueous Cell Viability Assay (Promega) was utilized. This assay measures cell
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viability by the reduction of MTS tetrazolium to formazan by viable cells, and relates absorbance
at 490 nm to number of viable cells. Twenty microliters of the MTS/PMS solution were added to
the existing media in each well using a multichannel pipette as per manufacturer’s directions,
and the plate was incubated at 37 °C and 5% CO2 for 1 hr. Absorbance was subsequently
measured using the Infinite 2000 PRO microplate reader (Tecan), selecting MTS assay mode.
Cell viability for each treatment condition was then calculated using the following formula: %
Viability = [(Treated cells - Blank)/(Cells only - Blank)]*100%.
For a qualitative assessment of cytotoxicity, the above protocol was carried out with the
following exceptions: 6-well plates of 70-80% confluent A549 cells were treated for 1 hour with
100 μL EGCG-S dilitions and DMSO controls. Following aspiration of reagents, addition of
fresh media, and incubation for 48 hours, images of cell morphology were obtained using a
Biostar inverted microscope (Reichert).
Antiviral Assay
A549 cells were grown for 24 hours in a 96-well plate, until 70-80% confluent. HSV-1
and treatment (100, 75, 50 and 25 μM EGCG-S or 2, 1.5, 1, and 0.5% DMSO controls) were
incubated at room temperature for 1 hr. One hundred microliters containing 50 μL HSV-1 and
brought up to the desired concentration of EGCG-S or DMSO were then placed in each well,
five wells per treatment, including media-only and HSV-1 only controls. After a 1 hour
incubation period, unadsorbed virus was removed, and 100 μL of fresh media was placed in each
well, including blank wells containing no cells. Cells were then incubated for 48 hours at 37 °C
and 5% CO2. Media was removed from the plate through shaking, and 100 μL of Viral ToxGlo
ATP Detection Buffer (Promega) was added to each well using a multichannel pipette as per
manufacturer’s directions. The plate was allowed to equilibrate for 15 min, and luminescence
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was read using the Infinite 2000 PRO microplate reader (Tecan). Cell viability was then plotted
against HSV-1 treatment using the following equation: % Viability = [(Cells infected with
treated HSV-1 - Blank)/(Cells only - Blank)]*100%.
Binding Assays
A549 cells were grown for 24 hours in a 96-well plate, until 70-80% confluent. The plate
was pre-incubated at 4 °C for 30 minutes, and media was shaken out of the plate. HSV-1 and
treatment (EGCG-S or DMSO control) were incubated at room temperature for 1 hr. On ice, 100
μL containing 50 μL HSV-1 and brought up to the desired concentration of EGCG-S or DMSO
were placed in each well, five wells per treatment, including media-only and HSV-1 only
controls. The plate was incubated for 1 hr at 4 °C, then unbound HSV-1 was carefully aspirated
with a multichannel pipette. 100 μL fresh media was added to each well, and the plate was
incubated at 37 °C and 5% CO2 for 48 hours. Subsequently, 100 μL of Viral ToxGlo ATP
Detection Buffer (Promega) was added to each well in addition to the existing media. After a 15
minute incubation at 37 °C and 5% CO2, luminescence was measured with the Infinite 2000
PRO microplate reader (Tecan). After subtraction of the blank measurement, average
luminescence values were plotted against HSV-1 treatment conditions.
For a qualitative assessment of HSV-1 binding inhibition, the above protocol was
performed in 6-well plates of 70-80% confluent A594 cells. Equal volumes of HSV-1 and
EGCG-S or DMSO controls were incubated together at room temperature for 1 hour, and 200
μL treated virus was placed in each well. HSV-1 only and media only controls were included.
Following aspiration of treated HSV-1, addition of fresh media, and incubation for 48 hours,
images of cell morphology were obtained using a Biostar inverted microscope (Reichert).
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Penetration Assays
The penetration assay was performed based on the protocol established by Harden et al.
(2009). Briefly, A549 cells were grown for 24 hours in a 96-well plate, until 70-80% confluent.
Media was removed by shaking, the plate was placed on ice, and 100 μL of HSV-1 were placed
in each well along with approximately 2 mL media. The plate was incubated at 4 °C for 2 hours,
to ensure attachment but not penetration of the HSV-1. At room temperature, EGCG-S was
added in order to bring the total volume in each well up to to the desired EGCG-S concentration
(75, 50, and 25 μM). Once media and DMSO controls were also added to their respective wells
at room temperature, viral penetration was allowed to take place for 10 min at 37 °C.
Subsequently, 100 μL of 1X PBS (pH 3.0) was added to each well to inactivate the virions. After
the solution was carefully removed from the plate using a multichannel pipette, 100 μL of fresh
10% FBS F-12K media was deposited into each well. Following a 48 hr incubation at 37 °C and
5% CO2, 100 μL Viral ToxGlo ATP Detection Buffer (Promega) was added to each well. The
plate was allowed to equilibrate for 15 min, and luminescence was read using the Infinite 2000
PRO microplate reader (Tecan).
The ability of EGCG-S to inhibit HSV-1 penetration was also analyzed through
automated cell counting. A549 cells were grown for 24 hours in a 6-well plate, until 70-80%
confluent. Media was removed, the plate was placed on ice, and 100 μL of HSV-1 were placed in
each well, along with approximately 2 mL media. The plate was incubated at 4 °C for 2 hours, to
ensure attachment but not penetration of the HSV-1. At room temperature, EGCG-S was added
to the existing contents of the plate in order to reach the desired concentrations, and cells were
incubated at 37 °C for 15 minutes to allow HSV-1 penetration to occur. The contents of each
well were aspirated, cells were washed with 1 mL of 1X PBS (pH 3.0) to inactivate the virions,
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and 2 mL fresh media was placed in each well. Cells were harvested in their own media by cell
scraping 48 hours post infection, and incubated 1:1 with 0.25% trypan blue for 30 sec. Ten
microliters of the stained cell mixture was loaded onto a slide and placed into the instrument.
Cell size and number was measured for each sample with the Countess II FL Automated Cell
Counter, and percent viability was recorded.
Statistical Analysis
For antiviral, binding, and penetration assays, sample standard deviation for each
condition was calculated using the STDEV.S function in Microsoft Excel, and outliers were
identified and rejected using Dixon’s Q-test.
For percent viability and percent inhibition, uncertainty is shown as relative standard
deviation. The equation

ߪ

ൌ ටቀ

2

ቁ ቀ

2

ቁ was utilized, where a and b are luminescence

values for cells treated with EGCG-S and cells only, and ߪ is sample standard deviation.
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RESULTS AND DISCUSSION

I. Cytotoxicity Study of Treatment of A549 cells with EGCG-S
In order to confirm the effects of the EGCG-S and DMSO on cell viability, A549 cells
were treated with concentrations of EGCG-S up to 100μM and DMSO up to 2%, respectively.
A549 cells grown in 6-well plates were incubated for 1 hr with EGCG-S dilutions of 75 and 100
μM and the corresponding DMSO control solutions, and allowed to grow for 48 hours. The
morphology of the A549 cells were observed, and images were captured through inverted
microscopy. Cells treated with EGCG-S appeared as healthy and confluent as the cells only
control (Figure 1). These results indicate that EGCG-S is not toxic to A549 cells at
concentrations of 100 μM and lower.
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Figure 1

Morphological Observation of A549 Cell Viability
in Response to EGCG-S Treatment

Figure 1 displays viability of A549 cells in response to EGCG-S treatment. In order to visually
determine the effect on cell morphology, A549 cells grown in 6-well plates were incubated with
100 μL EGCG-S (and corresponding DMSO controls) per well. Images were taken through a
Biostar inverted microscope (Reichert) following 48 hrs incubation at 37 °C and 5% CO2.

A549 cells were also grown in a 96-well plate were incubated for 1 hr with 100 μL of
EGCG-s at concentrations of 50, 75, and 100 μM, as well as with media for a cells-only control.
To ensure any cytotoxic effects were not due to the vehicle solution, 2, 1.5, and 1% DMSO
controls were also tested. An MTS assay was performed following a 48 hr incubation, and
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absorbance at 490 nm, which directly correlates to cell viability, was measured. Cell viability
was calculated as percent of control, and all concentrations of EGCG-S tested were shown to
have a percent viability comparable to the cells-only control, as well as to the DMSO controls.
This demonstrates that neither EGCG-S nor the corresponding DMSO controls exert any toxic
effects on A549 cells, up to a concentration of 100 μM.

Figure 2

Percent Viability of A549 Cells Treated with EGCG-S

Figure 2 displays percent viability of A549 cells treated with EGCG-S. A549 cells were treated
with 100 μL EGCG-S dilutions or the corresponding DMSO controls. After 48 hrs, the CellTiter
96 AQueous Non-Radioactive Cell Proliferation Assay (Promega) was used to measure cell
viability. For each condition, the mean and standard deviation of four wells were calculated and
corrected by subtracting the blank signal. Cell viability was calculated by %
ൌ
ቀ













ቁ ൈ 100%. Error bars show relative standard deviation,
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calculated by the following equation, where a is the absorbance value for cells treated with
EGCG-S, b is the cells only value, and ߪ is sample standard deviation, determined by the
STDEV.S function in Excel:

ߪ

ൌ ටቀ

2

ቁ ቀ

ቁ

2

II. Antiviral Effect of Treatment with EGCG-S
To demonstrate the anti-HSV-1 activity of EGCG-S, A549 cells were infected for 1 hr
with 100 μL of a solution containing 50 μL of previously treated HSV-1 in varying
concentrations of EGCG-S. After an incubation period of 48 hrs, luminescence was measured
following addition of Viral ToxGlo ATP Detection Buffer (Promega) (Figure 3A). Percent
inhibition was calculated for each concentration of EGCG-S (Figure 3B). Antiviral effect was
seen in a dose-dependent manner, with highest inhibition being observed by 100 μM EGCG-S
(85.87 ± 0.07 %), followed by 75 μM (29.51 ± 0.13 %) (Table 1).

Figure 3 A
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Figure 3 A displays the antiviral effect of EGCG-S on HSV-1. A549 cells were infected with
EGCG-S-treated HSV-1 for 1 hr, and incubated 48 hrs. Luminescence was measured following
addition of 100 μL Viral ToxGlo ATP Detection Buffer (Promega) per well. For each condition,
the mean of four wells was calculated and corrected by subtracting the blank signal. Sample
standard deviation was initially determined with the STDEV.S function in Excel, and the error
bar values were calculated by the following equation, where is a represents the standard
deviation of the treated sample and b represents the standard deviation of the blank
measurement: ߪ ൌ ඥ
cell viability.

2

2



. Increase in luminescence is directly correlated to increase in

Figure 3 B

Figure 3 B displays the percent inhibition of HSV-1 infection exerted by varying concentrations
of EGCG-S. Percent Inhibition was calculated with the following equation, using the average
luminescence
values
shown
in
Figure
3
A:
%
ൌ
ሺ

ቀ


ሺ



ି1ሻିሺ
ሻିሺ

ሻ

ି1
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ቁ ൈ 100%. Error bars show relative standard deviation,

calculated by the following equation, where a is the luminescence value for cells treated with
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EGCG-S, b is the cells only value, and ߪ is sample standard deviation, determined by the
STDEV.S function in Excel:

ߪ

ൌ ටቀ

2

ቁ ቀ

ቁ

2

Table 1
EGCG-S (μM)

100

75

50

25

Inhibition (%)

85.87 ± 0.07

29.51 ± 0.13

15.6 ± 0.2

4.6 ± 0.7

Table 1 lists values of percent inhibition of cytopathic effect induced by HSV-1 infection, as
shown graphically in Figure 3 B. Results are shown as mean ± relative standard deviation.

III. Inhibition of Binding by EGCG-S
To test if the antiviral effect of EGCG-S is due to inhibition at the initial binding step,
HSV-1 treated with varying concentrations of EGCG-S was used to infect A549 cells for 1 hr at
4 °C, a temperature that allows for binding but not penetration of the virions. After 48 hours, cell
morphology was observed to determine if EGCG-S protected the cells from cytopathic effect
(CPE), characterized by rounding and lifting of the cells. It was shown that 75 μM and 50 μM
EGCG-S appear to have a protective effect on HSV-1 cells infected with HSV-1, suggesting that
these concentrations inhibit HSV-1 infection under binding conditions (Figure 4).
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Figure 4

Morphological Observation of HSV-1 Binding Inhibition by EGCG-S

Figure 4 displays the differences in morphology of A549 cells infected with EGCG-S-treated
HSV-1 or HSV-1 alone. HSV-1 was pre-incubated with equal volumes of EGCG-S or DMSO
vehicle control for 1 hr. Confluent monolayers of A549 cells grown in 6-well plates were prechilled at 4 °C for 30 min, then infected with treated HSV-1 for 1 hr at 4 °C, rocking plates
intermittently every 15 minutes. Cells were washed once with cold PBS and unbound virus was
aspirated. Fresh 10% F-12K media was placed in each well, and images were taken through a
Biostar inverted microscope (Reichert) following 48 hrs incubation at 37 °C and 5% CO2.

For a quantitative assessment of HSV-1 binding inhibition, HSV-1 treated with varying
concentrations of EGCG-S was used to infect A549 cells for 1 hr at 4 °C. After 48 hours
incubation followed by detection of luminescence through the use of the Viral ToxGlo Assay
(Promega), a dose-dependent reduction of HSV-1 binding was observed (Figure 5A). Treatment
with 100 μM EGCG-S resulted in almost 100% inhibition of HSV-1 binding (97.89 ± 0.11 %),
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while treatment with 75 μM EGCG-S resulted in 43.4 ± 0.2 % inhibition of binding. When
compared to percent inhibition of EGCG-S tested at other time points in the viral reproductive
cycle, EGCG-S was shown to show the highest percent inhibition at the binding step (Figure 5B,
Table 2). These results suggest a possible antiviral mechanism of action of EGCG-S against
HSV-1.

Figure 5 A

Figure 5 A displays the results of the investigation of HSV-1 binding inhibition by EGCG-S.
Luminescence was measured following addition of 100 μL Viral ToxGlo ATP Detection Buffer
(Promega) per well. For each condition, the mean and standard deviation of four wells were
calculated and corrected by subtracting the blank signal. Error bars represent sample standard
deviation, calculated using the STDEV.S function in Excel.
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Figure 5 B

Figure 5 B represents the luminescence data from Figure 5 A above as percent inhibition of
HSV-1 binding by EGCG-S. Percent Inhibition was calculated with the following equation,
using the average luminescence values shown in Figure 5 A: %
ൌ
ሺ

ቀ


ሺ



ି1ሻିሺ
ሻିሺ

ሻ

ି1
ሻ

ି1

ቁ ൈ 100%. Error bars show relative standard deviation,

calculated by the following equation, where a is the luminescence value for cells treated with
EGCG-S, b is the cells only value, and ߪ is sample standard deviation, determined by the
STDEV.S function in Excel:
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Table 2
EGCG-S (μM)

100

75

50

25

Inhibition (%)

97.89 ± 0.11

43.4 ± 0.2

22.2 ± 0.2

7.3 ± 0.9

Table 2 lists percent inhibition of HSV-1 binding by varying concentrations of EGCG-S from
Figure 5 B, shown above. Results are displayed as mean ± relative standard deviation.

27

IV. Inhibition of Penetration by EGCG-S
In order to determine if the inhibition by EGCG-S occurred at the time point in which the
virions penetrated the A549 cells, a 96-well plate of A549 cells was infected with HSV-1 at 4 °C
for 2 hours, to ensure attachment but not penetration of the HSV-1, then treated for 10 minutes
with varying concentrations of EGCG-S at 37 °C, during the penetration step. Luminescence was
measured following addition of 100 μL Viral ToxGlo ATP Detection Buffer (Promega) (Figure
6A). Of the concentrations tested, 100 μM EGCG-S showed the highest inhibition of penetration
(63.23 ± 0.13 %) (Figure 6B). Interestingly, 75 and 50 μM showed similar levels of inhibition of
HSV-1 penetration, at 44.9 ± 0.2 % and 40.5 ± 0.2 %, respectively (Table 3).

Figure 6 A

Figure 6 A displays the inhibition of HSV-1 by EGCG-S at the penetration step of the viral
reproductive cycle. A 96-well plate of A549 cells was infected with HSV-1 at 4 °C for 2 hours,
to ensure attachment but not penetration of the HSV-1, then treated for 10 minutes with varying
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concentrations of EGCG-S at 37 °C, during the penetration step. Luminescence was measured
following addition of 100 μL Viral ToxGlo ATP Detection Buffer (Promega) per well. For each
condition, the mean and standard deviation of four wells were calculated and corrected by
subtracting the blank signal. Error bars represent sample standard deviation, initially determined
through the STDEV.S function in Excel, then calculated by the following equation, where is a
represents the standard deviation of the treated sample and b represents the standard deviation of
2

the blank measurement: ߪ ൌ ඥ

2
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Figure 6 B

Figure 6 B displays percent inhibition of HSV-1 penetration by varying concentrations of
EGCG-S. Percent Inhibition was calculated with the following equation, using the average
luminescence
values
shown
in
Figure
6
A:
%
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calculated by the following equation, where a is the luminescence value for cells treated with
EGCG-S, b is the cells only value, and ߪ is sample standard deviation, determined by the
STDEV.S function in Excel:
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Table 3
EGCG-S (μM)

100

75

50

25

Inhibition (%)

63.23 ± 0.13

44.9 ± 0.2

40.5 ± 0.2

17.5 ± 0.3

Table 3 displays the percent inhibition of HSV-1 penetration by EGCG-S, represented in Figure
6 B above. Values are listed as mean ± relative standard deviation.

The effect on penetration was also analyzed using an automated cell counter. Cells were
infected with treated HSV-1 under penetration conditions as described above. Cells were
harvested 48 hours post infection, and incubated 1:1 with 0.25% trypan blue for 30 sec. Cell size
was measured for each sample with the Countess II FL Automated Cell Counter, and percent
viability was recorded. Of the two concentrations tested, treatment with 100 μM EGCG-S
yielded a percent viability of 30.63%, the percent viability closest to the cells only control.
However, since the cells only control was only 50.35% viable, further optimization of the
protocol may be necessary.
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Figure 7 A

Automated Cell Counter Analysis of HSV-1 Penetration Inhibition
by EGCG-S

Figure 7 A displays the cell count and average measured diameter of all living or dead cells in
the penetration assay. A 6-well plate of A549 cells was infected with HSV-1 at 4 °C for 2 hours,
to ensure attachment but not penetration of HSV-1, then treated for 10 minutes with varying
concentrations of EGCG-S at 37 °C during the penetration step. Cells were harvested 48 hours
post infection, and incubated 1:1 with 0.25% trypan blue for 30 sec. Cell size and number was
measured for each sample with the Countess II FL Automated Cell Counter, and percent viability
was recorded.

31

Figure 7 B

Figure 7 B graphically summarizes the data from Figure 7 A above, displaying the cell viability
data resulting from the inhibition of HSV-1 penetration by two concentrations of EGCG-S. Cell
size and number was measured for each sample, and percent viability was calculated by the
Countess II FL Automated Cell Counter.

Table 4
Conditions

100 μM
EGCG-S

2% DMSO

75 μM
EGCG-S

Viability
(%)

30.63

24.8

10.37

1.5% DMSO Cells Only HSV-1 Only
8.57

50.35

12.21

Table 4 displays the percent viability of cells infected by EGCG-S-treated HSV-1 at the
penetration step, shown graphically in Figure 7 B above. Percent viability was calculated by the
Countess II FL Automated Cell Counter.

32

CONCLUSIONS
HSV-1 is a neurotropic virus, the causative agent of lifelong, recurring oral and genital
lesions, and represents a significant public health issue (Looker et al., 2015). Although
nucleoside analog antivirals such as acyclovir are available, the existence of multidrug resistant
strains of HSV-1 necessitates a novel therapeutic strategy that is more efficacious, possesses less
potential for drug resistance, and functions through a different mode of action (James and
Prichard, 2014). EGCG, a polyphenolic compound derived from green tea, is a small molecule
that functions as a broad spectrum antiviral, and has been shown to effectively decrease HSV-1
infectivity in cell culture (Colpitts and Schang, 2014). EGCG-S, a stable, lipophilic derivative of
EGCG, has been utilized in a topical formulation that demonstrated inhibition of HSV-1
symptoms in a clinically significant manner (Zhao et al., 2015). However, the antiviral
mechanism of action of EGCG-S has not been fully investigated at the cellular level. Since
prevention of initial viral viral binding is a main antiviral mode exerted by green tea catechins
and EGCG against a diverse range of viruses (Xu et al., 2017; Colpitts and Schang, 2014), it is
hypothesized that EGCG-S functions to inhibit HSV-1 infection by a similar mechanism.
In the current study, it was first established that EGCG-S did not have a cytotoxic effect
on the cells, but did function as an antiviral against HSV-1. Visual observation of A549 cell
morphology following EGCG-S treatment as well as quantitative assessment through the MTS
assay revealed cells to be healthy and confluent, showing percent viability comparable to the
control, and demonstrating that EGCG-S is non-toxic up to a concentration of 100 μM. The
antiviral effect of EGCG-S against HSV-1 was confirmed through inverted microscopy in
addition to quantitative luminescent assays that detect ATP as a measure of cell viability.
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Antiviral effect was seen in a dose-dependent manner, with highest inhibition being observed by
100 μM EGCG-S (85.87 ± 0.07%), followed by 75 μM (29.51 ± 0.13%).
Once the antiviral effect of EGCG-S against HSV-1 had been demonstrated, the ability of
EGCG-S to inhibit HSV-1 entry at the initial binding step was evaluated through inverted
microscopy and luminescence-based assays. Treatment of virions with 50 and 75 μM EGCG-S
prior to infection was morphologically shown to have a protective effect on A549 cells.
Quantitatively, a dose-dependent reduction of HSV-1 binding was observed, with 75 μM EGCGS resulting in 43.4 ± 0.2% inhibition of HSV-1 binding, and 100 μM EGCG-S treatment
resulting in almost 100% inhibition of HSV-1 binding (97.89 ± 0.11%).
To further investigate the ability of EGCG-S to inhibit HSV-1 entry, inhibition of HSV-1
penetration, which occurs through endocytosis or fusion of the viral and host lipid envelopes,
was investigated. Preliminary studies performed with an automated cell counter demonstrated
that treatment with 100 μM EGCG-S yielded a percent cell viability of 30.63%, the percent
viability closest to the cells only control (50.35% viable), although further optimization of the
protocol is necessary. Luminescent assays revealed that 100 μM EGCG-S resulted in 63.23 ±
0.13% inhibition of penetration, while 75 and 50 μM showed similar levels of inhibition of HSV1 penetration to one another, at 44.9 ± 0.2% and 40.5 ± 0.2%, respectively.
When compared to assessments of overall antiviral ability as well as to assays
investigating inhibition of HSV-1 penetration, EGCG-S was shown to exhibit the highest percent
inhibition at the binding step. These results indicate a possible antiviral mechanism of action of
EGCG-S against HSV-1, although further assay repetitions along with quantitative PCR and
flow cytometry studies are suggested to further elucidate this mechanism. Taken together, the
results of this study suggest EGCG-S inhibition of the binding step of the HSV-1 infection cycle.
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